SCHEMBL4078324

SCHEMBL4078324

Nc1cccc2cccc(F)c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.45
RPS6KA3 P51812 1/20 0.45
MELK Q14680 1/20 0.45
STK24 Q9Y6E0 1/20 0.45
CYP3A4 P08684 8/20 0.42
ALDH1A1 P00352 6/20 0.42
TSHR P16473 5/20 0.42
HSD17B10 Q99714 4/20 0.42
HPGD P15428 3/20 0.42
KEAP1 Q14145 1/20 0.42
CYP1A2 P05177 4/20 0.41
CYP1A1 P04798 1/20 0.41
CYP1B1 Q16678 1/20 0.41
REV1 Q9UBZ9 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
NPC1 O15118 1/20 0.39
GAA P10253 1/20 0.39
RAB9A P51151 1/20 0.39
TYMS P04818 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30706725 1.00 JAK2 (0.45) JAK2RPS6KA3MELKSTK24CYP3A4
SCHEMBL29788341 0.81 ALDH1A1 (0.53) CYP3A4ALDH1A1TSHRHSD17B10HPGD
SCHEMBL29349435 0.81 JAK2 (0.54) JAK2RPS6KA3MELKSTK24CYP3A4
SCHEMBL4112541 0.81 ALDH1A1 (0.53) CYP3A4ALDH1A1TSHRHSD17B10HPGD
SCHEMBL65699 0.81 JAK2 (0.54) JAK2RPS6KA3MELKSTK24CYP3A4
SCHEMBL14742902 0.78 ALDH1A1 (0.59) JAK2RPS6KA3MELKSTK24CYP3A4
Ammonia Solution, Strong SCHEMBL2638226 0.78 JAK2 (0.52) JAK2RPS6KA3MELKSTK24CYP3A4
Hydrochloric Acid SCHEMBL11277860 0.78 JAK2 (0.52) JAK2RPS6KA3MELKSTK24CYP3A4
SCHEMBL9627127 0.78 JAK2 (0.52) JAK2RPS6KA3MELKSTK24CYP3A4
Fluoride SCHEMBL11274176 0.78 JAK2 (0.52) JAK2RPS6KA3MELKSTK24CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114891199-A Preparation method of poly (fluorophenyl ester) polymer with high dielectric constant 西安交通大学 2022-08-12 CN claimed
WO-2007049124-A1 METHOD OF MAKING 8-FLUORO-NAPHTHALEN-1-YLAMINE AND RELATED COMPOUNDS PFIZER PRODUCTS INC. (US) 2007-05-03 WO claimed
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-01-15 US disclosed
CN-119677749-A Azaquinazoline pan KRAS inhibitors 米拉蒂治疗股份有限公司 2025-03-21 CN disclosed
CN-114891199-B Preparation method of polyfluorophenyl ester polymer with high dielectric constant 西安交通大学 2024-06-25 CN disclosed
WO-2023244615-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-21 WO disclosed
US-20230212170-A1 INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF ANTENGENE DISCOVERY LIMITED (CN) 2023-07-06 US disclosed
US-20230212170-A1 INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF ANTENGENE DISCOVERY LIMITED (CN) 2023-07-06 US disclosed
US-20230212170-A1 INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF ANTENGENE DISCOVERY LIMITED (CN) 2023-07-06 US disclosed
EP-4161934-A1 INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF ANTENGENE DISCOVERY LIMITED (CN) 2023-04-12 EP disclosed
CN-115836072-A Inhibitors of KRAS G12C protein and uses thereof 上海德琪医药科技有限公司 2023-03-21 CN disclosed
CN-1863784-B 2-naphthylimino-1,3-thiazine derivative SHIONOGI & CO 2010-11-17 CN disclosed
US-7482339-B2 2-Naphthylimino-1,3-thiazine derivative SHIONOGI AND CO., LTD. (JP) 2009-01-27 US disclosed
JP-2007119461-A 8-FLUORO-NAPHTHALENE-1-YLAMINE AND RELATED COMPOUNDS PFIZER PROD INC 2007-05-17 JP disclosed
WO-2007049124-A1 METHOD OF MAKING 8-FLUORO-NAPHTHALEN-1-YLAMINE AND RELATED COMPOUNDS PFIZER PRODUCTS INC. (US) 2007-05-03 WO disclosed
WO-2007049124-A1 METHOD OF MAKING 8-FLUORO-NAPHTHALEN-1-YLAMINE AND RELATED COMPOUNDS PFIZER PRODUCTS INC. (US) 2007-05-03 WO disclosed
WO-2007049124-A1 METHOD OF MAKING 8-FLUORO-NAPHTHALEN-1-YLAMINE AND RELATED COMPOUNDS PFIZER PRODUCTS INC. (US) 2007-05-03 WO disclosed
US-20060281738-A1 2-Naphthylimino-1,3-thiazine derivative SHIONOGI AND CO., LTD. (JP) 2006-12-14 US disclosed
CN-1863784-A 2-naphthylimino-1,3-thiazine derivative SHIONOGI & CO (JP) 2006-11-15 CN disclosed
EP-1659117-A1 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2006-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281738-A1 2-Naphthylimino-1,3-thiazine derivative NPM1, OXTR, CYP2S1 JAK2 175/4885RPS6KA3 2227/4885MELK 3543/4885
US-20230212170-A1 INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF KRAS, NRAS, HRAS JAK2 990/4885RPS6KA3 1079/4885MELK 1120/4885
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS JAK2 674/4885RPS6KA3 799/4885MELK 2599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.